HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
- Author:
Somy YOON
1
;
Gwang Hyeon EOM
Author Information
- Publication Type:Review
- Keywords: Histone deacetylases; Histone deacetylase inhibitors; Neoplasms; Cardiovascular diseases
- MeSH: Acetylation; Cardiovascular Diseases; Chromatin; Epigenomics; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Inflammation; Neurodegenerative Diseases; Phenotype; Tail; United States Food and Drug Administration
- From:Chonnam Medical Journal 2016;52(1):1-11
- CountryRepublic of Korea
- Language:English
- Abstract: Histone deacetylases (HDACs) are epigenetic regulators that regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. HDACs are also post-transcriptional modifiers that regulate the protein acetylation implicated in several pathophysiologic states. HDAC inhibitors have been highlighted as a novel category of anti-cancer drugs. To date, four HDAC inhibitors, Vorinostat, Romidepsin, Panobinostat, and Belinostat, have been approved by the United States Food and Drug Administration. Principally, these HDAC inhibitors are used for hematologic cancers in clinic with less severe side effects. Clinical trials are continuously expanding to address other types of cancer and also nonmalignant diseases. HDAC inhibition also results in beneficial outcomes in various types of neurodegenerative diseases, inflammation disorders, and cardiovascular diseases. In this review, we will briefly discuss 1) the roles of HDACs in the acquisition of a cancer's phenotype and the general outcome of the HDAC inhibitors in cancer, 2) the functional relevance of HDACs in cardiovascular diseases and the possible therapeutic implications of HDAC inhibitors in cardiovascular disease.
